Skip to main content
. 2022 May 26;11(23):4491–4500. doi: 10.1002/cam4.4834

FIGURE 1.

FIGURE 1

Alectinib showed consistent superiority in PFS over crizotinib. Kaplan–Meier curves were drawn for comparing the PFS between alectinib and crizotinib in all patients (A) and patients receiving no or only 1 cycle of chemotherapy prior to TKI (B). Prognostic factors for PFS were further analyzed using multivariate Cox regression model in all patients (C).